DeciBio Estimates Clinical Oncology Liquid Biopsy Market At ~$200M, "Just Scratching The Surface" Of Opportunity

Thursday, January 3, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Newly released market report details market size, growth, competitors, and keys to success

SANTA MONICA, Calif., Jan. 3, 2019 /PRNewswire/ -- DeciBio Consulting, LLC, a precision medicine-focused strategy consulting

and market intelligence firm, has released their 2019 Liquid Biopsy Market Report and Stakeholder Toolkit. DeciBio's analysis estimates the clinical oncology liquid biopsy manufacturers' market at ~$200 million in 2018, growing at ~40% annually to reach $1 billion by 2023.

The liquid biopsy market has seen dramatic investment in the past few years, with liquid biopsy companies raising over $4 billion since 2015. DeciBio expects growth in the liquid biopsy market, led by such companies as GRAIL and Guardant Health, to be driven by technological improvements, demonstration of clinical utility, and expanded inclusion in clinical guidelines. This growth could be moderated by such factors as limited or delayed reimbursement by commercial payers and unforeseen biological limitations that require additional R&D investment, such as variability in circulating analyte levels.

Even at a market size of one billion dollars in 5 years, DeciBio founding partner Stephane Budel, Ph.D., believes that will just be scratching the surface. "The reality is the liquid biopsy market can be orders of magnitude larger than the tissue testing market," says Budel, "because it can be used throughout the patient journey."

The report also covers the competitive landscape and market analysis, and provides guidelines for entrepreneurs, investors, payers and biopharma partners interested in entering the liquid biopsy space. It is now available for purchase on DeciBio's website at https://www.decibio.com/intelligence/liquid-biopsy-fad-or-future-market-report/.

About DeciBioDeciBio is a strategy consulting and market intelligence firm focused on precision medicine. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy and corporate due diligence. The company also offers market intelligence products, including several life science market reports and data visualization and analysis platforms for immuno-oncology, liquid biopsy, cancer biomarkers and more.

Contactinfo@decibio.com 310-451-4510DeciBio Consulting, LLC

 

Cision View original content:http://www.prnewswire.com/news-releases/decibio-estimates-clinical-oncology-liquid-biopsy-market-at-200m-just-scratching-the-surface-of-opportunity-300772267.html

SOURCE DeciBio Consulting, LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store